StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)

Equities research analysts at StockNews.com initiated coverage on shares of OpGen (NASDAQ:OPGN) in a research note issued on Saturday. The firm set a “sell” rating on the medical research company’s stock.

OpGen Stock Up 42.3 %

OpGen stock opened at $0.75 on Friday. The business has a 50 day moving average price of $1.33 and a two-hundred day moving average price of $1.94. OpGen has a 12 month low of $0.53 and a 12 month high of $9.90.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.